Mark S Sonders

US Patent:

7381542, Jun 3, 2008

Filed:

Dec 19, 2001

Appl. No.:

10/380614

Inventors:

James Bunzow - Portland OR, US
David K. Grandy - Portland OR, US
Mark Sonders - Portland OR, US

Assignee:

Oregon Health & Science University - Portland OR

International Classification:

C12N 15/00
C12N 15/85
C12N 15/63
C07H 21/04
C07K 14/00
C12N 1/21

US Classification:

435 691, 435325, 4353201, 4352523, 536 231, 536 235, 536 2431, 530350

Abstract:

The present invention relates to novel mammalian biogenic amine receptor proteins and genes that encode such proteins. The invention is directed toward the isolation and characterization of mammalian trace amine receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to rat and human homologues of a mammalian trace amine receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian trace amine receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian trace amine receptor proteins encoded therein. The invention also provides methods for screening compounds in vitro that are capable of binding to the mammalian trace amine receptor proteins of the invention, and further characterizing the binding properties of such compounds and functional consequences thereof in comparison with known trace amine receptor agonists and antagonists. Improved methods of pharmacological screening are provided thereby.

US Patent:

47090944, Nov 24, 1987

Filed:

Jul 10, 1986

Appl. No.:

6/884150

Inventors:

Eckard Weber - Portland OR
Mark Sonders - Portland OR
John F. Keana - Eugene OR

Assignee:

State of Oregon, acting by and through the Oregon State Board of Higher
Education, acting for and on behalf of the Oregon Health Sciences
University and the University of Oregon - Portland OR

International Classification:

C07C12912

US Classification:

564238

Abstract:

1,3-Disubstituted-guanidines, e. g. , of the formula ##STR1## wherein R and R' are hydrocarbon groups which preferably are the same, e. g. , 1,3-dibutyl-guanidine, 1,3-diphenyl-guanidine and 1,3-di-o-tolyl-guanidine, are highly selective ligands for sigma brain receptors and are useful in the diagnosis and treatment of hallucination associated psychotic mental illness and chronic mental depression. Tritium labeled 1,3-di-(o-tolyl)-guanidine is useful as a screening tool for compounds having selective sigma receptor binding activity, as it is displaced from isolated mammalian brain membrane to which it is bound portionately to the activity of such a compound.